Filana Therapeutics, Inc. Cash Flow Conversion Efficiency
Filana Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has a cash flow conversion efficiency ratio of -0.061x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($63.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Filana Therapeutics, Inc. (2022–2025)
Cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. This chart illustrates how Filana Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Filana Therapeutics, Inc. for real-time trading data and today's change.
Filana Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Filana Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Filana Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filana Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see FLNA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
-0.173x |
|
IDENTILLECT TECHN. O.N.
F:8ID
|
N/A |
|
AB Electrolux (publ)
ST:ELUX-A
|
0.528x |
|
Native Mineral Resources Holdings Ltd
AU:NMR
|
-0.815x |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
0.129x |
|
Singsongholdin
KO:006880
|
-0.080x |
|
Findi Ltd
AU:FND
|
-0.483x |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
0.059x |
Annual Cash Flow Conversion Efficiency for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. Review Filana Therapeutics, Inc. financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more